



**scipher**  
MEDICINE

The Precision Immunology Company

# Matching each patient with their most effective therapy

**\$552B**

wasted in healthcare  
due to ineffective  
drug spend

**10+**

years of research  
underpin our AI platform  
to identify blood-based  
therapy selection  
biomarkers

**5**

Prism® tests  
launched in 5 years,  
starting with  
PrismRA in 2021

**\$42B**

autoimmune  
disease TAM

**10k+**

patients in industry's  
largest clinico-genomic  
data lake from tested  
patients



Prism® blood tests enables payers, PBMs and providers to prescribe existing drugs more effectively.




Clinico-genomic data from tested patients allows pharma to drive precision medicine in preclinical pipeline.

**225 million patients** are prescribed  
drugs they don't respond to.


**Response rate** for top 10 selling  
drugs is below **30%**.

# \$552 billion in drug spend wasted in complex diseases every year



10x larger problem in complex diseases compared to oncology.

# Autoimmune disease is largest contributor to ineffective drug spend



# We've unlocked the potential of RNA analysis

Precision Medicine 1.0

**DNA**



Oncology


Precision Medicine 2.0

**RNA** (gene expression)



Complex diseases

# spectra<sup>®</sup> identifies patient's unique molecular disease signature from RNA data




Allows us to determine which drug target the patient will respond to.

And develop biomarkers for drug response.

Whole blood RNAseq data from a patient is superimposed on the protein network of human cells and lights up the molecular processes that make up disease biology.

# Prism<sup>®</sup> test pipeline developed in collaboration with payers and PBMs

Therapy selection test starting with autoimmune diseases.



Launched 2020



2022 launch




In development

# The Prism<sup>®</sup> test

A ubiquitous test addressing a \$42bn market opportunity.

One test, multiple diseases and therapies.



# We started with the largest opportunity first, anti-TNF drugs

**\$33B**

annual sales of anti-TNFs,  
world's largest drug class.

**65%**

of patients do **not respond**.




# PrismRA<sup>®</sup> blood test predicting non-response to anti-TNFs

90%  
prediction  
accuracy

Patient  
outcomes  
improves by  
40%

Potential  
healthcare  
savings of  
\$7bn




23-BIOMARKER PANEL


Allows rheumatoid arthritis patients with inadequate response to anti-TNFs to go on cheaper, more effective alternative therapy from day one without unnecessary side effects.

# Clinical outcomes studies show reduction in cost while improving outcomes

Reduces cost by 38%




4x more patients respond to therapy




# 15% of providers using test 12 months after launch with 85% repeat ordering rate

## Cumulative ordering providers



## Repeat ordering



# Strong momentum with payers and PBMs 12 months after launch

23

Signed payer/PBM  
contracts

Top-3 PBM in the US

Top-5 BCBS plan

Largest health plan GPO

Largest Managed Medicaid plan


Currently accessible to 21 million patients.

# Prism<sup>IBD</sup>® to be launched in 2022

**+90%**  
prediction  
accuracy

Patient  
outcomes  
improve by  
**30%**

Potential  
healthcare  
savings of  
**\$3B**



Predicts response to anti-TNF therapies in **ulcerative colitis patients**